



21 September 2022

AGM Date and Closing Date for Director Nominations



RE-ELECTION OF DIRECTORS NOMINATIONS DUE BY 29 SEPTEMBER 2022

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the research, development and commercialisation of clinically validated cannabinoid medicines, wishes to advise that, in accordance with ASX Listing Rule 3.13.1, it intends to hold its Annual General Meeting (AGM) on Thursday, 17 November 2022.

An item of business on the AGM agenda will be the re-election of Directors. The closing date for the receipt of nominations from persons wishing to be considered for election as a director is Thursday 29 September 2022.

Any nominations must be received at the Company's registered office no later than 5.00pm (Perth time) on Thursday 29 September 2022.

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.



For further information
please contact

Company

Dr Oludare Odumosu
Managing Director & CEO
☎ +1 909 855 0675
✉ oodumosu@zeliratx.com

Investors

Ronn Bechler
Executive Director, Automic Group
☎ +61 400 009 774
✉ ronn.bechler@automicgroup.com.au

About Zelira Therapeutics

Australia

Level 3, 101 St Georges Terrace
Perth WA 6000, AUSTRALIA
☎ +61 8 6558 0886
Fax: +61 8 6316 3337
✉ enquiries@zeliratx.com
www.zeliratx.com
ACN 103 782 378

USA

5110 Campus Drive, Suite 150
Plymouth Meeting, PA 19462
United States Of America
☎ +1 484-630-0650

About Zelira www.zeliratx.com



Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) Zelira is a leading global biopharmaceutical company in the research, development and commercialisation of clinically validated cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions including insomnia, autism and chronic non-cancer pain as well as offering over the counter [OTC] products.

Zelira's Rx business generates revenue from two proprietary medications, HOPE® and ZENIVOL®. The Company has two proprietary formulations under the HOPE® brand that are generating revenue in Australia, Washington, D.C., Pennsylvania and Louisiana.

Zelira is also generating revenue in Australia from its proprietary and patented ZENIVOL® – the world's first clinically validated cannabinoid drug for treatment of chronic insomnia. Zelira will also be expanding commercialisation of ZENIVOL® into Germany via its German commercialisation partner AdjuPharm GmbH following recent approval from German regulatory authority BfArM.

Zelira's OTC products in the oral and dermatology health care sectors are also generating revenue. Zelira, in partnership with SprinJeneCBD, launched a full line of oral care products, currently generating revenue in the US. The SprinJeneCBD toothpaste product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilising proprietary and patented technology. Zelira also launched in 2021 the RAF FIVE™ brand, which consists of five OTC acne treatment products using a proprietary formulation incorporating cannabidiol (CBD).



Zelira has developed Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology under the brand name Zyraydi, that solves the problem of non-uniformity and separation of cannabinoid from powder bed, opening new ways to develop pharmaceutical grade solid oral dosage forms such as capsules and tablets. Zelira will be assessing opportunities for commercialisation of this technology.

The Company conducts its work in partnership with world-leading researchers and organisations which since inception includes Curtin University in Perth, Australia; the Telethon Kids Institute in Perth, Australia; the University of Western Australia, in Perth, Australia; St Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

For further information, please visit: zeliratx.com